Cellectar Biosciences to present preclinical data on CLR 121225 at the AACR Special Conference on Pancreatic Cancer.
Quiver AI Summary
Cellectar Biosciences, Inc. announced that an abstract has been accepted for a poster presentation at the American Association for Cancer Research Special Conference on Pancreatic Cancer Research, scheduled for September 28 to October 1 in Boston. The poster will focus on preclinical data for CLR 121225, a novel actinium-based radio conjugate targeting hypoxic pancreatic ductal adenocarcinoma, with promising results shown in animal models. Jarrod Longcor, the company's COO, expressed excitement about presenting the data and advancing the drug's development. Cellectar is centered on cancer treatment innovations utilizing its proprietary drug delivery platform and has several products in its pipeline along with designations from the FDA for its lead asset, iopofosine I 131.
Potential Positives
- Abstract accepted for poster presentation at a prestigious conference, highlighting the company's engagement in significant cancer research.
- Presentation will showcase promising preclinical data for CLR 121225, demonstrating its potential effectiveness in treating hypoxic pancreatic ductal adenocarcinoma.
- Company's focus on a proprietary Phospholipid Drug Conjugate™ (PDC) platform underscores its innovative approach in cancer treatment, aiming for improved efficacy and safety.
- Additional advancements in IND-enabling activities for CLR 121225 suggest progress towards future clinical applications and potential market entry.
Potential Negatives
- The announcement emphasizes ongoing clinical trials and preclinical data without providing definitive results, which may indicate a lack of more advanced progress in drug development.
- The release contains extensive forward-looking statements, suggesting a reliance on uncertain future outcomes, which could raise concerns among investors regarding the company's stability and future performance.
- The mention of potential risks and uncertainties, particularly related to FDA and EMA regulatory pathways, may signal challenges ahead for product approvals and commercialization efforts.
FAQ
What is the focus of Cellectar Biosciences, Inc.?
Cellectar Biosciences focuses on discovering and developing drugs for cancer treatment, utilizing their proprietary Phospholipid Drug Conjugate™ delivery platform.
When will Cellectar present their research at the AACR conference?
Cellectar will present their research on September 30, 2025, from 6-9 p.m. during the AACR Special Conference.
What is CLR 121225?
CLR 121225 is a novel actinium-based radio conjugate designed to treat hypoxic pancreatic ductal adenocarcinoma and other solid tumors.
Who will present the poster at the AACR conference?
The poster will be presented by Jarrod Longcor, the chief operating officer of Cellectar Biosciences.
What are the benefits of the PDC delivery platform?
The PDC delivery platform aims to improve treatment efficacy and safety by minimizing off-target effects in cancer therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLRB Insider Trading Activity
$CLRB insiders have traded $CLRB stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CLRB stock by insiders over the last 6 months:
- JAMES V CARUSO (Chief Executive Officer) purchased 10,000 shares for an estimated $49,900
- JARROD LONGCOR (Chief Operating Officer) purchased 10,000 shares for an estimated $49,900
- CHAD J KOLEAN (Chief Financial Officer) purchased 5,000 shares for an estimated $24,950
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLRB Hedge Fund Activity
We have seen 2 institutional investors add shares of $CLRB stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAADER BANK AKTIENGESELLSCHAFT removed 172,940 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,229,603
- VANGUARD GROUP INC removed 57,395 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $408,078
- UBS GROUP AG removed 30,678 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $218,120
- GEODE CAPITAL MANAGEMENT, LLC removed 14,780 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $105,085
- SQUAREPOINT OPS LLC removed 12,362 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $87,893
- CITADEL ADVISORS LLC removed 11,442 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $81,352
- BLACKROCK, INC. removed 7,693 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $54,697
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.
“We are excited to present our poster at the AACR Special Conference on Pancreatic Cancer, further showcasing the potential of CLR 121225 for solid tumors,” said Jarrod Longcor, chief operating officer of Cellectar. “We are encouraged that preclinical studies to date have demonstrated excellent activity, biodistribution and uptake of CLR 225 across multiple solid tumor animal models and are currently advancing IND-enabling activities.”
Details of the poster presentation are as follows:
| Title: | “Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225, a Novel Actinium-Based Radio-Conjugate” |
| Poster: | B032 |
| Date/Time: | Tuesday, September 30, 6-9 p.m. Presenter: Jarrod Longcor |
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X , LinkedIn , and Facebook .
Forward Looking Statements Disclaimer
This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the FDA and EMA regulatory pathways, ability to execute strategic alternatives, identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2024, and our Form 10-Q for the quarterly period ending June 30, 2025. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
INVESTORS:
Anne Marie Fields
Precision AQ
212-362-1200
[email protected]
